美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果

目的分析美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者的临床效果。方法选取2016年8月至2018年2月76例冠心病心力衰竭患者,随机分为对照组与观察组,每组38例。对照组给予常规治疗,观察组在对照组治疗的基础上给予美托洛尔联合曲美他嗪治疗。比较两组治疗效果。结果治疗后,观察组患者的血浆脑钠肽(BNP)、收缩压(SBP)、心率(HR)、左心室舒张末期内径(LVEDD)、左室射血分数(LVEF)、左心室收缩末期内径(LVESD)等指标均明显低于对照组(P<0.05),LVEF高于对照组(P<0.05)。结论美托洛尔联合曲美他嗪治疗冠心病心力衰竭的效果显著,值得临床推广应用。

Clinical effect of metoprolol combined with trimetazidine on patients with coronary heart disease and heart failure

Objective To analyze the clinical effect of metoprolol combined with trimetazidine on coronary heart disease and heart failure.Methods Seventy-six patients with coronary heart disease and heart failure treated from August 2016 to February 2018 were selected.They were divided into control group and observation group,with 38 cases in each group.The control group was given routine treatment,while the observation group was given metoprolol combined with trimetazidine on the basis of the control group.Results After treatment,the plasma brain natriuretic peptide(BNP),systolic blood pressure(SBP),heart rate(HR),left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD) in the observation group were significantly lower than those in the control group(P<0.05).The level of LVEF was higher than that of control group(P<0.05).Conclusions Metoprolol combined with curvature has significant effect coronary heart failure,which is worthy of clinical application.